Fluorogen-activating proteins enable low-background fluorescence imaging by inducing emission only upon fluorogen binding. However, spectral diversification often involves coordinated optimization of fluorogens and their protein partners, while compatibility with structurally diverse fluorophore scaffolds remains limited. Here, we present a fluorogen-centered strategy for multispectral fluorescence activation using a single fluorescein-targeting single-chain variable fragment (scFv), E2. Intramolecularly quenched fluorogens were constructed through a heterodimeric architecture integrating a fluorescein recognition module with spectrally distinct fluorophores, including rhodamine, dicyanoisophorone, and Cy7. Systematic optimization of the linker structure and fluorophore identity enabled efficient self-quenching in the free state and fluorescence activation upon E2 binding, producing enhancements of 63.7-, 28.2-, and 45.0-fold across visible to near-infrared channels. Spectroscopic and fluorescence lifetime analyses suggested that fluorescence activation is associated with perturbation of intramolecular quenching interactions. The optimized fluorogen L4-Cy7 binds E2 with a Kd value of 1.8 μM. Genetic fusion of E2 to tumor-targeting scFvs enabled receptor-specific activation of L4-Cy7 and rapid imaging of prostate and breast cancer cells without washing after fluorogen addition. Overall, this work establishes a modular fluorogen-centered framework for multispectral activation using a unified protein scaffold and provides an optimized near-infrared fluorogen for targeted cellular imaging.
Pu Meng, Zhuang Shao, Kai Cui et al.· Organic and biomolecular che...· 0 citations
Lymphatic malformations (LMs), particularly intractable subtypes with diffuse growth, pose significant clinical challenges due to incomplete resection, high recurrence rate, and adverse effects of conventional therapies such as sclerotherapy with bleomycin (BLM). Herein, we developed a multifunctional metal-polyphenol nanoplatform through hyaluronic acid (HA) matrix-regulated biomineralization of Fe3+ and polyphenolic tannic acid (TA), followed by loading with Bleomycin (Fe(Ⅲ)-TA/BLM@HA). This nanoassembly integrates photoacoustic (PA) imaging guidance, targeted delivery, and synergistic photothermal-sclerosis therapy against LMs. The Fe(Ⅲ)-TA/BLM@HA nanoassemblies can specifically target lymphatic endothelial cells (LECs) via HA-LYVE-1 interaction. The nanoassemblies exhibit excellent colloidal stability, remarkable photothermal conversion, and strong PA signals for real-time guided precise intralymphatic injection. Fe(Ⅲ)-TA/BLM@HA binds lymphatic endothelial cells (LECs) in a concentration-dependent manner, and exerts synergistic cytotoxicity, outperforming free BLM and Fe(Ⅲ)-TA@HA. In Balb/c mouse LM models, PA imaging visualized the spatiotemporal distribution of Fe(Ⅲ)-TA/BLM@HA post percutaneous injection. Notably, Fe(Ⅲ)-TA/BLM@HA plus 650 nm NIR laser raised lesion temperature by 13.6 °C, resolving LMs in 1-2 cycles vs 3-4 cycles for free BLM. This study confirms Fe(Ⅲ)-TA/BLM@HA as a safe, effective option for intractable LMs, with substantial translational potential for vascular anomaly management.
Xin Zhang, Saisai Yue, Peisen Zhang et al.· ACS Applied Materials and In...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.